BUND FINANCE › Stocks › GSK
GSK plc (GSK)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is -1.50% below its 50-day average.
- It is -7.25% below its 200-day average (long-term downtrend).
- It sits at 17% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | GBP 24.7B | GBP 29.3B | GBP 30.3B | GBP 31.4B | GBP 32.7B |
| Net income | GBP 4.4B | GBP 15.0B | GBP 4.9B | GBP 2.6B | GBP 5.7B |
| EPS (diluted) | 2.70 | 7.32 | 2.40 | 1.24 | 2.78 |
| Gross margin | 67.0% | 67.4% | 71.8% | 71.2% | 72.4% |
| Operating margin | 17.6% | 21.9% | 22.2% | 12.8% | 24.3% |
| Net margin | 17.8% | 51.0% | 16.3% | 8.2% | 17.5% |
| Free cash flow | GBP 5.3B | GBP 6.8B | GBP 4.4B | GBP 3.6B | GBP 4.8B |
| Total debt | GBP 24.2B | GBP 21.0B | GBP 18.0B | GBP 17.0B | GBP 17.7B |
| Cash | GBP 4.3B | GBP 3.7B | GBP 2.9B | GBP 3.7B | GBP 3.4B |
Compound annual growth: revenue 7.2% · net income 6.9% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | — | 12.4x | 27.1x |
| EV / EBITDA | — | 9.4x | 16.5x |
| Operating margin | 20.4% | — | 3.6% |
| Net margin | 13.0% | — | -0.0% |
| Debt / equity | 2.84 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation. The company reports in another currency: amounts are shown in that currency.
About GSK plc
GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urog…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice